Leucine in Midlife Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions
Major Depression
Interventions
DRUG

L-leucine

"L-leucine is an essential amino acid used to competitively inhibit kynurenine uptake into the brain via the large neutral amino acid transporter (LAT1).~The proposed dose for L-leucine is 4.31 g/day, administered orally."

DRUG

L-lysine

"L-lysine monohydrochloride is also an essential amino acid. It serves as an active comparator to control for general effects on brain protein synthesis and enters the brain through separate cationic amino acid transporters.~The proposed dose for L-lysine is 6 g/day, administered orally"

Trial Locations (1)

30322

RECRUITING

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

Emory University

OTHER